Visual and Anatomic Outcomes following Cataract Surgery in Patients with Pre-operative Macular Edema Due to Retinal Vein Occlusions Managed with Intravitreal anti-VEGF.
Aged
Angiogenesis Inhibitors
/ administration & dosage
Bevacizumab
/ administration & dosage
Cataract
/ complications
Cataract Extraction
Dexamethasone
/ administration & dosage
Female
Follow-Up Studies
Glucocorticoids
/ administration & dosage
Humans
Macular Edema
/ diagnosis
Male
Preoperative Period
Ranibizumab
/ administration & dosage
Retinal Vein Occlusion
/ complications
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
Anti-vascular endothelial growth factor injections
cataract
cystoid macular edema
retinal vein occlusion
Journal
Seminars in ophthalmology
ISSN: 1744-5205
Titre abrégé: Semin Ophthalmol
Pays: England
ID NLM: 8610759
Informations de publication
Date de publication:
18 May 2020
18 May 2020
Historique:
pubmed:
30
7
2020
medline:
2
7
2021
entrez:
30
7
2020
Statut:
ppublish
Résumé
The purpose of this study was to investigate the visual and anatomic outcomes in patients with macular edema due to retinal vein occlusions (RVO) who were actively managed with intravitreal anti-vascular endothelial growth factor (VEGF) before and after cataract surgery. Retrospective, cohort study of all patients with RVO who underwent cataract surgery and were receiving intravitreal anti-VEGF injections from January 1st, 2012 through October 31st, 2018. There were 31 eyes that underwent cataract surgery and received at least one intravitreal anti-VEGF injection for a diagnosis of RVO within 6 months prior to surgery. Data collected included the development of subretinal or intraretinal macular fluid in the 6 months following surgery, timing of injections, number of injections, best corrected visual acuity (BCVA), and central subfield thickness (CST). There was a significant improvement between pre- and post-operative BCVA when comparing all eyes ( Patients with cataracts who are actively managed for macular edema due to RVO with anti-VEGF agents may undergo cataract surgery, knowing they will have a transient increase in macular thickness that resolves without adjusting the frequency of intravitreal injections and is not visually significant.
Identifiants
pubmed: 32721186
doi: 10.1080/08820538.2020.1772319
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Glucocorticoids
0
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
Dexamethasone
7S5I7G3JQL
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM